Gene therapy for heart failure caused by BAG3 mutation
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests an experimental gene therapy (AFTX-201) designed to address the genetic cause of heart failure in people with a specific BAG3 gene mutation. It aims to improve heart function and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a confirmed BAG3 gene mutation that causes heart muscle weakness.
- Your heart's pumping function (ejection fraction) is less than 50%.
- You experience heart failure symptoms like shortness of breath or fatigue (NYHA class II or III).
- You weigh 120 kg (about 264 lbs) or less.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental gene therapy called ALXN2350 for people with dilated cardiomyopathy caused by a specific genetic change in the BAG3 gene. It aims to see if the therapy can improve heart function and slow disease progression.
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
This study follows people with a specific genetic change (in the BAG3 gene) that causes heart muscle weakness, to learn more about how the condition progresses over time. It does not test a new drug, but it helps researchers understand the disease better, which may lead to future treatments.
This study follows adults with a specific genetic mutation (BAG3) that causes heart muscle weakness. Researchers will track how the disease develops over time to better understand it and help improve future treatments.
This trial tests a gene therapy injected into the heart to help it recover after a previous heart attack. It may be an option for people with stable heart failure who are not eligible for standard procedures like stents or bypass surgery.
This trial tests a one-time gene therapy for people with heart failure who still have normal pumping strength (preserved ejection fraction). It aims to improve how heart cells handle calcium, which may help the heart relax better and ease symptoms.
Hear when a new Dilated Cardiomyopathy (DCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.